News

cardiologists heart doctors

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

heart drugs with stethoscope

An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care. 

SCAI has shared a new call to action as an observance of American Heart Month. The group is asking Congress to pass new pieces of legislation that could improve care for PAD patients and get important medical devices in the hands of interventional cardiologists.

Cerepak Detachable Coil Systems

Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

the words "FDA recall" on a board

New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness. 

heart surgery surgeons

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Open surgical bypass is the gold standard, but endovascular therapies may provide value for high-risk patients with long femoropopliteal lesions.

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense. 

Intravascular lithotripsy (IVL) Shockwave Medical PCI PAD CAD Disrupt PAD Disrupt CAD SCAI 2022

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

The tricuspid valve anatomy is ofrten complicated for transcatheter structural heart interventions (TTVR) by the placement of pacemaker or ICD leads.

Joao Cavalcante, MD, of the Minneapolis Heart Institute, discusses new structural heart interventions to treat tricuspid valve regurgitation.

Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology.

Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).

The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

Around the web

Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's  FDA 510(k)-pending photon-counting CT scanner.